- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06754527
Options for Navigating Talking About Risk and Adolescent Choices (ON-TRAC)
December 30, 2024 updated by: Rhode Island Hospital
Emotion Regulation Intervention to Prevent Substance Use Among Youth in the Child Welfare System
This study will examine the effectiveness of ON-TRAC (Options for Navigating Talking about Risk and Adolescent Choices), which is an online substance use prevention program that also teaches emotion regulation skills.
200 adolescents, 12-15 years of age, will be randomized to ON-TRAC or a wait list comparison group (who will be offered the intervention at the end of their study participation) to determine impact on substance use, emotion regulation abilities, mental health symptoms, and other risk behavior outcomes.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Stephanie Parade, PhD
- Phone Number: 401-793-8247
- Email: stephanie_parade@brown.edu
Study Contact Backup
- Name: Christopher Houck, PhD
- Phone Number: 401-793-8333
- Email: CHouck@brownhealth.org
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Contact with the Rhode Island child welfare system
- Caregiver who is a parent/guardian of a child who experienced maltreatment
- Caregiver who speaks English or Spanish
- Caregiver who does not have developmental delays
- Adolescent who is between 12-15 years of age
- Adolescent who is fluent in English
- Adolescent who has active follow-up with the Rhode Island child welfare system due to an indicated finding of abuse or neglect in the past year
Exclusion Criteria:
- Adolescent who cannot read at a 4th grade level
- Adolescent who has a sibling who has participated in the program
- Adolescent who has developmental delays
- Adolescent who lacks parental consent for the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: ON-TRAC Intervention
Web-based emotion regulation and substance use intervention
|
Online tablet-based intervention that teaches youth emotion regulation skills and integrates substance use prevention content
|
|
No Intervention: Waitlist Control
Control participants are assessed on the same schedule as the treatment condition and offered the intervention after the 8-month follow-up
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Timeline Follow Back
Time Frame: Baseline, 2-, 5-, and 8-months
|
A calendar assisted daily substance use estimation method obtained by interview.
Days used will serve as primary outcome.
More days used represent more substance use.
|
Baseline, 2-, 5-, and 8-months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Drinking Refusal Self-Efficacy Questionnaire - Shortened Adolescent Version
Time Frame: Baseline, 2-, 5-, and 8-months
|
Assesses self-efficacy to resist alcohol use.
Scores range from 9 to 54.
Higher scores represent greater drinking refusal self-efficacy.
|
Baseline, 2-, 5-, and 8-months
|
|
Drinking Refusal Self-Efficacy Questionnaire - Shortened Adolescent Version (Adapted for Marijuana Use)
Time Frame: Baseline, 2-, 5-, and 8-months
|
Assesses self-efficacy to resist marijuana use.
Scores range from 9 to 54.
Higher scores represent greater marijuana refusal self-efficacy.
|
Baseline, 2-, 5-, and 8-months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Youth Risk Behavior Surveillance Survey
Time Frame: Baseline, 2-, 5-, and 8-months
|
Single items assess other risk behaviors such as sexual risk or violence behaviors.
Endorsement of each individual item indicates engagement in the risk behavior.
|
Baseline, 2-, 5-, and 8-months
|
|
Patient-Reported Outcome Measures Information System - Anger Scale
Time Frame: Baseline, 2-, 5-, and 8-months
|
Assesses symptoms of mental health and social functioning.
Scores range from 5 to 25.
Higher scores indicate greater anger.
|
Baseline, 2-, 5-, and 8-months
|
|
Difficulties in Emotion Regulation Scale
Time Frame: Baseline, 2-, 5-, and 8-months
|
Assesses perceptions of emotion regulation skills.
Scores range from 18-90.
Higher scores indicate more difficulty regulating emotions.
|
Baseline, 2-, 5-, and 8-months
|
|
Emotion Regulation Behaviors Scale
Time Frame: Baseline, 2-, 5-, and 8-months
|
Assesses use of emotion regulation behaviors taught in the intervention.
Scores range from 9 to 36.
Higher scores indicate more frequent use of the strategies taught.
|
Baseline, 2-, 5-, and 8-months
|
|
Diagnostic Analysis of Nonverbal Accuracy-2
Time Frame: Baseline, 2-, and 8-months
|
Computer-based measure that asks participants to identify the emotion of facial expressions displayed in photographs.
Scores range from 0 to 20.
Higher scores indicate better identification of emotions.
|
Baseline, 2-, and 8-months
|
|
Behavioral Indicator of Resiliency to Distress
Time Frame: Baseline, 2-, and 8-months
|
Computerized frustration task in which participants are given the option to quit at any time.
Scores range from 0 to 300 seconds.
Higher scores indicate more persistence in a frustrating task.
|
Baseline, 2-, and 8-months
|
|
Self-Efficacy Questionnaire for Children
Time Frame: Baseline, 2-, 5-, and 8-months
|
Assesses perception of ability to cope with negative emotions.
Scores range from 8 to 40.
Higher scores indicate greater perceived ability to cope with negative emotions.
|
Baseline, 2-, 5-, and 8-months
|
|
Implicit Theories of Emotions for Children - Self subscale
Time Frame: Baseline, 2-, 5-, and 8-months
|
Assesses beliefs about the controllability of emotions.
Scores range from 6 to 36.
Higher scores indicate stronger beliefs about the controllability of emotions.
|
Baseline, 2-, 5-, and 8-months
|
|
Respiratory sinus arrhythmia
Time Frame: Baseline and 2-month follow up
|
Collected in response to virtual reality scenes, RSA is a physiological marker of emotion regulation processes calculated from heart rate variability as an index of parasympathetic activity.
|
Baseline and 2-month follow up
|
|
Feasibility and Acceptability Scale
Time Frame: 2-month follow-up (ON-TRAC group only)
|
Assesses acceptability of digital interventions to assess implementation outcomes.
Scores range from 5 to 25.
Higher scores indicate greater acceptability of the intervention.
|
2-month follow-up (ON-TRAC group only)
|
|
System Usability Scale
Time Frame: 2-month follow-up (ON-TRAC group only)
|
Assesses usability of technology programs to assess implementation outcomes.
Scores range from 10 to 50.
Higher scores indicate greater usability of the intervention.
|
2-month follow-up (ON-TRAC group only)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
March 1, 2026
Primary Completion (Estimated)
September 1, 2028
Study Completion (Estimated)
February 1, 2029
Study Registration Dates
First Submitted
December 23, 2024
First Submitted That Met QC Criteria
December 30, 2024
First Posted (Actual)
March 25, 2025
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
December 30, 2024
Last Verified
December 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ON-TRAC (unknown Protocol ID)
- R61DA059785 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance Use
-
University of ArkansasNational Center for Advancing Translational Sciences (NCATS)RecruitingParenting | Substance Use Treatment | Perinatal Substance UseUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use | Substance Use Disorders | Cannabis Use | Alcohol Use, UnspecifiedUnited States
-
Indiana UniversityPatient-Centered Outcomes Research InstituteRecruitingAdolescent | Alcohol Use | Mild Alcohol Use Disorder | Mild Substance Use DisorderUnited States
-
Woebot HealthNational Institute on Drug Abuse (NIDA); Stanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Emory UniversityNational Institute on Drug Abuse (NIDA); Georgia Institute of Technology; CUNYCompletedSubstance-Related Disorders | Substance Abuse, Intravenous | Substance Use Disorders | Opioid Use | Substance Abuse | Opioid-use Disorder | Opioid Use Disorder, Severe | Substance WithdrawalUnited States
-
University of California, San FranciscoTobacco Related Disease Research ProgramRecruitingTobacco Use Disorder | Substance Use Disorder (SUD)United States
-
Icahn School of Medicine at Mount SinaiNational Institute on Drug Abuse (NIDA)Active, not recruitingSubstance Use Disorder | Cocaine Use DisorderUnited States
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Indiana UniversityNational Institute on Drug Abuse (NIDA)RecruitingSubstance Use Disorders | Nicotine Use DisorderUnited States
-
Spark Biomedical, Inc.National Institute on Alcohol Abuse and Alcoholism (NIAAA); Baylor College... and other collaboratorsRecruitingSubstance Use Disorders | Alcohol Use Disorder | Alcohol Abuse | Substance Use Disorders Alcohol Use Withdrawal StateUnited States
Clinical Trials on ON-TRAC
-
Dana-Farber Cancer InstituteRecruitingCancer | Anxiety | SurvivorshipUnited States
-
Transplant Genomics, Inc.Medical University of South Carolina; University of California, Los Angeles; Northwestern... and other collaboratorsNot yet recruitingKidney Transplant Rejection | Biopsy | Biomarkers / Blood | Immunosuppression Management | Subclinical Rejection
-
University of Wisconsin, MadisonNational Institute on Drug Abuse (NIDA)CompletedHepatitis C | HIV | Substance Use DisordersUnited States
-
University of Wisconsin, MadisonNational Institute on Aging (NIA)Completed
-
Harvard UniversityCompletedDepression | Anxiety | Trauma | Behavior ProblemsUnited States
-
University Medical Center GroningenRecruiting
-
Rhode Island HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedRisk Behavior | Risk Reduction | Emotion RegulationUnited States
-
Memorial Sloan Kettering Cancer CenterTakedaActive, not recruitingB-Cell Lymphoma | Large B-cell Lymphoma | DLBCL, Nos Genetic Subtypes | Mediastinal Large B-cell Lymphoma | High-grade B Cell LymphomaUnited States
-
Transplant Genomics, Inc.University of British Columbia; University of California, Los Angeles; University...Recruiting
-
Transplant Genomics, Inc.Recruiting